CELTIC BIOTECH

Celtic Biotech is an early stage company developing novel therapeutic products for the treatment of solid cancers and pain in humans. Derived from specialised receptor binding proteins found in snake venom, these product candidates have the potential to reduce treatment costs, increase survival, and improve quality-of-life for cancer patients... Celtic Biotech is focusing its research on solid tumours including non-small-cell lung cancer (NSCLC), breast, prostate, ovarian and cervical cancer as initial targets. These are some of the leading causes of cancer deaths worldwide, and there is a large unmet need in terms of effective therapies, particularly for late stage disease.